Journal Mobile Options
Table of Contents
7, No. 1, 2012
Issue release date: February 2012
Free Access
Breast Care 2012;7:39–44
(DOI:10.1159/000336531)
Original Article · Originalarbeit

Use of Adjuvant Endocrine Therapy in Postmenopausal Hormone Receptor-Positive Breast Cancer at German Breast Cancer Centers and University Hospitals - Results of an Enquiry (Adjuvant Endocrine Therapy Enquiry)

Kolben T.a · Engelmann S.b · Maurer S.a · Kolben M.a
aFrauenarztpraxis und Wolfart-Klinik Gräfelfing, bPraxis für Gynäkologie und Geburtshilfe, München, Germany

Abstract

Background: Many studies about the adjuvant endocrine therapy of postmenopausal patients with hormone receptor-positive breast cancer have shown significant superiority of aromatase inhibitors (AIs) compared to tamoxifen only. Within these studies, different AIs (anastrozole, letrozole, exemestane) and treatment strategies (upfront, switch, extended adjuvant) were applied. Material and Methods: The intention of our enquiry was to evaluate the implementation of the results of these studies in German breast cancer centers and university hospitals. Questionnaires were sent to 200 breast cancer centers and university hospitals (returns: 108). Results: Our enquiry showed that most centers preferred anastrozole as upfront therapy in patients with an intermediate or high risk of relapse. Furthermore, during AI therapy, additional bisphosphonate treatment was applied ‘always' in only 9% of cases, and in 78% of cases of proved osteopenia/osteoporosis. Surprisingly, 50% of the participating centers do not exclude AIs in premenopausal women. Conclusion: At the time of our enquiry, anastrozole as upfront therapy was consistent with the recommendations of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) from 2009. Compared to tamoxifen, AIs increase the risk of osteoporosis, which can, however, be prevented and treated with concomitant bisphosphonate therapy. The rare use of bisphosphonates as well as contraindicated AI therapy in premenopausal patients show amongst others the substantial need for more information.

 goto top of outline Author Contacts

Prof. Dr. Martin Kolben, Praxis für Frauengesundheit und Wolfart-Klinik Gräfelfing, Bahnhofstrasse 9, 82166 Gräfelfing, Germany, Tel. +49 89 8986737-1, Fax -2, info@frauenarzt-graefelfing.de


 goto top of outline Article Information

Published online: February 13, 2012
Number of Print Pages : 6


 goto top of outline Publication Details

Breast Care (Multidisciplinary Journal for Research, Diagnosis and Therapy)

Vol. 7, No. 1, Year 2012 (Cover Date: February 2012)

Journal Editor: Harbeck N. (Köln), Thomssen C. (Halle/Saale), Gnant M. (Wien)
ISSN: 1661-3791 (Print), eISSN: 1661-3805 (Online)

For additional information: http://www.karger.com/BRC


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.